Morgan Stanley Starts CRISPR Therapeutics (CRSP) at Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $49.39 -1.2%
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
19 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Underweight rating and a price target of $37.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $60.82 yesterday.
You May Also Be Interested In
- Craig-Hallum Starts OraSure Technologies (OSUR) at Buy, PT $7
- Needham Assumes Benchmark (BHE) at Buy
- Northland Starts Unusual Machines (UMAC) at Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
